The Medicare savings that the American College of Physicans says could be saved by focusing on generics is estimated to total $1.4 billion.
The FDA has approved Bristol-Myers Squibb’s Opdivo as a treatment for renal cell carcinoma in some patients.
Earlier this year, California and Oregon passed laws allowing pharmacists to prescribe birth control to patients. As the measure is set to roll out in the first half of 2016, the New York Times has reported on the growing trend of states allowing pharmacists to prescribe contraceptives, noting its potential impact on medically underserved populations. “I feel strongly that this is what’s best for women’s health in the 21st century, and I also feel it will have repercussions for decreasing poverty because one of the key things for women in poverty is unintended pregnancy,” Oregon Rep. Knute Buehler, the Republican who sponsored Oregon’s law, told NYT. (New York Times)
Greenstone received final approval from the Food and Drug Administration for its generic Zyvox.
CVS Health has opted to only offer one of the two new PCSK9 inhibitors on its CVS/caremark commercial formularies.
The new indication provides another option for the estimated 300,000 patients who will undergo hip replacements in a year.
Perrigo is buying a Crohn’s disease treatment from AstraZeneca.
A 15-member board composed will govern the combined company and Pfizer CEO Ian Read will be CEO of the combined company and Allergan CEO Brent Saunders will be the president and COO.
In preparation for this launch, Mission has expanded its sales force and increased promotional efforts to reach more primary care and internal medicine healthcare providers.
Specialty medications represent only 1% of all prescriptions but, in 2014, these medications resulted in over 31% of all drug spending.